Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
Moody's Investors Service on Friday lowered its rating outlook on drugmaker Eli Lilly and Co. to "negative"
from "table" due in part to the looming expiration of patents protecting key drugs from generic competition.
The unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern
Asia.
Lilly’s lobbying spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional debate
over health care reform peaked during the last quarter of 2009.
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Eli Lilly and Co. discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Over the course of her life, the last surviving great-grandchild of pharmaceutical magnate Eli Lilly gave away much of her
inheritance.
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total
of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way
of Central Indiana a total of $1 million over the next four years as a “challenge to CEOs and other community leaders to step
up their giving.”
Hoping to increase sales in China’s rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead
with
plans to invest $100 million in venture capital in the region over the next several years.
Hoosiers fretting over Eli Lilly and Co.’s future have new reasons to worry. Even in the best of times, the pharmaceutical business is a highstakes gambit, with every company’s fate hinging on ushering new blockbusters through its R&D pipeline. But those stakes never have been higher at Lilly, which faces a devastating onslaught of patent expirations between now and 2014. The problem isn’t just Zyprexa, the antipsychotic that loses U.S. and European protection in 2011. It accounted for 26 percent…
It hasn’t been easy the last few years to be a shareholder of Eli Lilly and Co. Lilly’s stock price has languished as the company’s vaunted drug pipeline has suffered hiccups and as legal troubles over its best-selling drug, Zyprexa, have lingered. So as Lilly shareholders gather April 16 for their annual meeting, two key questions hang in the air. Both center on Zyprexa, an anti-schizophrenia drug, which accounts for one-quarter of Lilly’s revenue and even more of its profit….
Derica Rice started figuring out his future the day he glanced in his mother’s refrigerator and actually paid attention to the insulin vials stored there. Eli Lilly and Co.’s new chief financial officer recalled being home at the end of a summer. He was fresh off an internship with another company and was in casual job talks with Lilly representatives. He had seen the clear vials his mother, Inez-a Type II diabetic-stored in her fridge, but he never read the…
Sure, Eli Lilly and Co. has a promising portfolio of new drugs and other potential blockbusters in the pipeline. But every time the Indianapolis drugmaker reports profits, Wall Street analysts spend much of their time slicing and dicing one number: Zyprexa sales. Their greatest fear: The schizophrenia medication will stop pulling its weight before other drugs pick up the slack, sapping sales and profits and further depressing the company’s already deflated stock. Indeed, the stakes are huge. Zyprexa sales in…
One of the main benefits touted by Lilly is that Strattera is the only ADHD drug on the market that is not a stimulant, meaning users are less likely to abuse it. The makers of Adderall and Concerta have advertised their drugs in magazines geared to parents of kids with ADHD. And Lilly has been running television ads aimed at adults who may not realize they have the disorder. ADHD symptoms include impulsivity, trouble concentrating, disorganization, procrastination and hyperactivity. Several…
Eli Lilly and Co. has sold clinical-research software it created to a veteran Indianapolis entrepreneur who plans to market it globally, potentially growing his startup company into one of the area’s largest technology firms. Joe Huffine, best known as co-founder of the technology consultancy Onex Inc., said his new firm, Maaguzi LLC, should benefit as the market for research software grows explosively. Maaguzi’s software allows researchers and patients to record data electronically instead of on paper. The software is geared…
